Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H13N5O9S2.2C5H14NO |
Molecular Weight | 643.731 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCO.C[N+](C)(C)CCO.CC1(C)[C@H](NC(=O)C(=N/OCC([O-])=O)\C2=CSC(N)=N2)C(=O)N1OS([O-])(=O)=O
InChI
InChIKey=FRVWKWRHJIDCFO-ZJFJOYJNSA-L
InChI=1S/C12H15N5O9S2.2C5H14NO/c1-12(2)8(10(21)17(12)26-28(22,23)24)15-9(20)7(16-25-3-6(18)19)5-4-27-11(13)14-5;2*1-6(2,3)4-5-7/h4,8H,3H2,1-2H3,(H2,13,14)(H,15,20)(H,18,19)(H,22,23,24);2*7H,4-5H2,1-3H3/q;2*+1/p-2/b16-7-;;/t8-;;/m1../s1
Tigemonam is a dialkylazetidinone derivative patented by E. R. Squibb and Sons, Inc. as a beta-lactam agent useful for the treatment of bacterial infections. Of the orally active beta-lactams, tigemonam is one of the most potent, with a spectrum of activity similar to that of aztreonam and highly resistant to hydrolysis by the beta-lactamase enzymes. Tigemonam inhibits 90% of Escherichia coli, Klebsiella spp., Proteus spp., Salmonella spp., Haemophilus influenzae and Branhamella catarrhalis tested. In localized infections, tigemonam also demonstrated excellent in vivo activity. In acute pyelonephritis in mice caused by Escherichia coli or Proteus sp., tigemonam was very effective. In a rat lung model with Klebsiella pneumoniae, tigemonam was active with a median effective dose of 46 mg/kg compared with 160 mg/kg for cefaclor and over 200 mg/kg for amoxicillin.
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C260
Created by
admin on Fri Dec 15 17:48:07 GMT 2023 , Edited by admin on Fri Dec 15 17:48:07 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Y-68
Created by
admin on Fri Dec 15 17:48:07 GMT 2023 , Edited by admin on Fri Dec 15 17:48:07 GMT 2023
|
PRIMARY | |||
|
m967
Created by
admin on Fri Dec 15 17:48:07 GMT 2023 , Edited by admin on Fri Dec 15 17:48:07 GMT 2023
|
PRIMARY | Merck Index | ||
|
14253084
Created by
admin on Fri Dec 15 17:48:07 GMT 2023 , Edited by admin on Fri Dec 15 17:48:07 GMT 2023
|
PRIMARY | |||
|
102916-21-2
Created by
admin on Fri Dec 15 17:48:07 GMT 2023 , Edited by admin on Fri Dec 15 17:48:07 GMT 2023
|
PRIMARY | |||
|
C152620
Created by
admin on Fri Dec 15 17:48:07 GMT 2023 , Edited by admin on Fri Dec 15 17:48:07 GMT 2023
|
PRIMARY | |||
|
648358RH17
Created by
admin on Fri Dec 15 17:48:07 GMT 2023 , Edited by admin on Fri Dec 15 17:48:07 GMT 2023
|
PRIMARY | |||
|
C052020
Created by
admin on Fri Dec 15 17:48:07 GMT 2023 , Edited by admin on Fri Dec 15 17:48:07 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD